trending Market Intelligence /marketintelligence/en/news-insights/trending/Uo_mmtNsQRLxlN4TyoN6Mw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Stemline Therapeutics plans common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Stemline Therapeutics plans common stock offering

Stemline Therapeutics Inc. plans to sell common stock in an underwritten public offering.

The net proceeds will go toward development of SL-401, which is currently being tested in a phase 2 clinical trial to treat blastic plasmacytoid dendritic cell neoplasm, a form of blood cancer. The funds will go toward clinical, regulatory, manufacturing and potential commercial activities of the drug, for which the company expects to file a biologics license application with the FDA in the second half.

It will also use the proceeds for clinical development of SL-801 and SL-701, two drugs in development to treat blood cancer, as well as research and development activities and other general corporate purposes.

Stemline will grant underwriters an option to purchase up to an additional 15% of the shares offered.

Jefferies LLC is acting as book-running manager for the offering.